<table>
<thead>
<tr>
<th>Clinical Trial Code</th>
<th>Title</th>
<th>Status</th>
<th>Intervention</th>
<th>Purpose</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT00855400</td>
<td>Intrathecal injection of autologous mesenchymal stem cells in ALS</td>
<td>Active, not recruiting</td>
<td>Interventions</td>
<td>Safety/Efficacy study of a mesenchymal stem cell transplantation</td>
</tr>
<tr>
<td>NCT01758510</td>
<td>Intraventricular injection of mesenchymal stem cells in ALS</td>
<td>Completed</td>
<td>Interventions</td>
<td>Safety of a microsurgery human neural stem cells transplantation into spinal cord</td>
</tr>
<tr>
<td>NCT00874783</td>
<td>Intrathecal injection of autologous mesenchymal stem cells in ALS</td>
<td>Enrolling by invitation only</td>
<td>Interventions</td>
<td>Safety of intrathecal injection of human neural stem cells in ALS</td>
</tr>
<tr>
<td>NCT01142856</td>
<td>Intrathecal injection of autologous mesenchymal stem cells in ALS</td>
<td>Active, not recruiting</td>
<td>Interventions</td>
<td>Safety of intravenous transplantation of bone marrow stromal cells</td>
</tr>
<tr>
<td>ABMSC</td>
<td>Intrathecal injection of autologous mesenchymal stem cells in ALS</td>
<td>Active, not recruiting</td>
<td>Interventions</td>
<td>Safety of autologous cultured mesenchymal bone marrow stromal cell transplantation (i.m.)</td>
</tr>
</tbody>
</table>

### Notes
- Abbreviations: ABMSC, Stem Cells, HNSC
- Clinical trial code: NCT00855400, NCT01758510, NCT00874783, NCT01142856
- Purpose: Safety/Efficacy, Interventional, Open label, Double blind, Randomized
- Location: USA, IRAN, Hanyang University, HNSC
- Proposed mechanism: Neuroprotection
- Dosage: 2U s.c. every other day, 0.5-2x the normal levels of IGF-I
- Analysis: 3-Intrathecal infusion of placebo 2 ml of placebo per kg, maximal values at 1.5-2x the normal range
- Time frame: Week 12, -8, -4, 0, 4, 8, 12, 16
- Additional data: For safety study patients' clinically unaffected (or only mildly affected) for the next patients group only following safety analysis.
- Other products: For the effect of the product on cellular and tissue levels
- Consideration: 110-141x10^6 and 188x10^6 respectively, for the next patients group only following safety analysis.
- Change in ALSFRS-R score: Time frame: Week 12, -8, -4, 0, 4, 8, 12, 16
- Number of patients with dose-limiting toxicities: Time frame: 2 years following treatment administration
- Forced vital capacity: Time frame: Every 3 months

### References